Who’s At Risk? While rare kidney diseases can affect anyone, some are more common in certain ethnic groups. IgA nephropathy, for example, is more prevalent in Asian communities, likely due to a mix of ...

The following is a summary of “Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy,” published in the ...

2019年2月， 中南大学湘雅二医院 在Kidney International（IF14.8000/1区）期刊上发表了一篇论文。在 发表6年后 ，因 图片组内重复 在pubpeer上被读者质疑。 论文题为 “Disulfide-bond A ...

This study is led by Dr. Haisheng Zhou (Department of Biochemistry and Molecular Biology, Anhui Medical University, China) and Dr. Guoling Zhou (Center for Computational Integrative Biology, ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway ...

BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of ...

LEADING charity Kidney Research UK has teamed up with the British Islamic Medical Association (BIMA) to use their combined ...